Top Tweets for #NETTER2
Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use.
https://t.co/LYDvp8lli1
#NETs #PRRT #NETTER2 #oncology
In our discussion with @helops79 and @ProfKHerrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS):
- #COMPETE
- #COMPOSE
- #NETTER1
- #NETTER2
#OncTwitter #MedTwitter #gism
PRRT - Radioligand Rx options in Neuroendocrine Tumors (NETs) with @helops79 & Ken Herrmann
✅ Different molecules
✅ Squencing
✅ Scans
Full discussion:
https://t.co/47CdydeimR
- https://t.co/r2ArmBayui
- Also on the “Oncology Brothers” podcast
#OncTwitter #MedTwitter
Is NETTER-2 a practice-changing trial? Hot off the press, commentary from @cives_mauro and Jon Strosberg @MoffittNews. #netter2 #neuroendocrine #prrt https://t.co/ZQJ9YZ63gw
Subgroup analysis on NETTER2 - @DrAngelaLamarca
@myESMO @GrupoGetne
#Cancer #ESMOGI24 #NETTER2 #OncoDaily #Oncology
https://t.co/hXoV1QbmTn
⭐Research highlight: The #NETTER2 trial establishes #radioligand therapy as a new first-line treatment for patients with high-grade, advanced gastroenteropancreatic neuroendocrine tumors — for whom evidence-based treatments are lacking. @TheLancet
https://t.co/fW8ZWN231q
#Subgroup analysis on #NETTER2 with #PRRT vs high dose SSA in #highKi67 #NETs CONFIRMS activity in
👉G2 and G3
👉Pancreas and SmallBowel
📝Lowest ORR in SmallBowel
👍🏻Short time to response
‼️Patient selection (not chemo pts)
@myESMO @GrupoGetne
#ESMOGI24
#ESMOAmbassadors
#NETTER2 presented again at #ENETS24
🚨Practice changing results👇🏻 and hopefully lots to come in this space
🚨PRRT 1st line benefits in G2-3 advanced GEP-NETs - NETTER2 #GI24
⬆️PFS by >12m median (vs SSA)👉🏻supports PRRT 1st line in G2-3
💥Unprecedented response rate: 43%👉🏻time for neoadj trial?
🤷🏻♀️G2-3 not bad with SSA: median PFS 8m & 9% ORR
👏🏻to team & PI Dr Singh @Sunnybrook!
📣 New data from #NETTER2 at #ENETS24 🔊 Investigators are as accurate as central review, and waterfall plots are amazing!! Practice changing and new options for more aggressive NET patients 💪🏼 @GrupoGetne @VHIO @Netespana @vallhebron
El próximo 19 de febrero hablaremos de los resultados del estudio #NETTER2 desde la perspectiva de Oncología y Medicina Nuclear.
Os esperamos‼️
Link registro👇🏻
https://t.co/UU6NVtm8NO
@OncBrothers @ASCO @PamelaKunzMD @TargetedOnc @YaleCancer @BijoyTelivala @RenoHemonc @Innov_Medicine @alshamsi2000 @ARosen380 @GIcancerDoc @realbowtiedoc @pashtoonkasi @ShaalanBeg Fantastic review. Initial read of #Netter2 super impressive but raises further questions about clinical impact vs operational rate limiting barriers for RLT therapies facing providers in multiple solid tumors.
#GI24 @ASCO Highlights w/ @PamelaKunzMD
- #CM8HW
- #EMERALD1
- #NETTER2
- #BESPOKE #GALAXY
Full discussion:
- https://t.co/WKk2yZQEEW
- https://t.co/d7QQijxChE
- Also on the “Oncology Brothers” podcast
#MedTwitter #OncTwitter #gism @TargetedOnc #MedEd #OncEd
@OncBrothers #NETTER2 interview with Simron Singh, MD can be seen @oncologytube here: https://t.co/3AvCSst0xr
Positive results from #netter2 trial, using PRRT in grade 2/ 3 #NeuroendocrineTumor
https://t.co/VS3dTwOO6G
Comments on my personal top 4 #GI24 abstracts (1/4):
1. NETTER-2
177Lu-DOTATATE vs high dose octreotide as 1L treatment of G2 or G3 GEP-NET (Ki67 between 10% and 55%):
⬆️ PFS (22.5 vs 8.5 mo, HR 0.27)
⬆️ ORR (43% vs 9%)
I did not expect such good numbers.
@OncoAlert
1/
Also really happy to see results on #NETTER2 trial using #prrt #theranostics #lutetium77 for grade2&3 patients with #pancreaticcancer #nets #neuroendocrinecancer #GI24 @netcanceraware @ASCO
5. #NETTER2: Lu-Dotatate vs SSA in 1L for advanced well differentiated Neuroendocrine tumors.
- Significant PFS improvement (22.8mos vs 8.5mos, HR: 0.276)
- “TTD in QoL remained similar b/w arms”????!!!
- Is this new SoC? Accessibility and AEs is still a real concern.
6/7
NETTER-2 shows PRRT gives huge PFS benefit over octreotide on first line treatment of Neuroendocrine disease (HR 0.26)
Is this PFS data practice changing for you ?
#GI24
Day 2 #GI24 @ASCO Highlights #CommunityOncology
1. #IMbrave151
2. GI/ColoRectal Ca in young adults
3. #ALPACA
4. #EXTEND
5. #NETTER2
6. #EMERALD1
#OncEd #MedEd #OncTwitter #MedTwitter #gism #crcsm #pancsm
1/7
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.1M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
108.8M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.2M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.5M followers
KATY PERRY
@katyperry
86.7M followers
Taylor Swift
@taylorswift13
80.5M followers
Lady Gaga
@ladygaga
72.1M followers
Kim Kardashian
@kimkardashian
69.3M followers
YouTube
@youtube
68.6M followers
Virat Kohli
@imvkohli
68.4M followers
Bill Gates
@billgates
63.4M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61M followers
X
@x
60.9M followers
CNN Breaking News
@cnnbrk
59.9M followers